Evidence-based recommendations for the use of continuous glucose monitoring in type 2 diabetes: the Italian guidelines A. Giaccari, G. Gliozzo, G. Ciccarelli, G. Di Giuseppe, C. Castellano, S. Cum, L. Delle Monache, M. Gallo, M. Lastretti, G. Medea, M. Monesi, R. Napoli, B. Pintaudi, E. Succurro, G. Turchetti Acta Diabetologica, 2026 Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients. Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel composed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (including basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, particularly for those with glycated hemoglobin levels ≥ 7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups. Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becoming mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Therapeutic Inertia in Dyslipidemia Management for Secondary Cardiovascular Prevention: Results from the Italian ITACARE-P Network Andrea Faggiano, Anna Gualeni, Lucia Barbieri, Gian Francesco Mureddu, Elio Venturini, Francesco Giallauria, Marco Ambrosetti, Matteo Ruzzolini, Francesco Maranta, Maria Vittoria Silverii, Laura Garau, Davide Garamella, Raffaele Napoli, Luigi Maresca, Gaetano Luca Panetta, Antonio Maggi, Stefano Carugo, Francesco Fattirolli, Pompilio Faggiano Journal of Clinical Medicine, 2025 Background/Objectives: This study assessed the proportion of secondary cardiovascular prevention patients who achieved low-density lipoprotein (LDL) cholesterol targets as per the 2019 ESC/EAS Dyslipidemia Guidelines. We also evaluated whether lipid-lowering therapies (LLTs) were adjusted in patients not meeting targets and analyzed the likelihood of these modifications achieving recommended levels. Methods: A multicenter, cross-sectional observational study retrospectively reviewed medical records of 1909 outpatients in 9 Italian cardiac rehabilitation/secondary prevention clinics from January 2023 to June 2024. Inclusion criteria included prior atherosclerotic cardiovascular disease (ASCVD) and recent LDL-cholesterol levels. Data included demographics, ASCVD presentation, lipid profiles, and LLTs. Patients at very high risk had LDL targets of ≤55 mg/dL, or ≤40 mg/dL for recurrent events within 2 years. Clinicians’ approaches to LLT modification in patients not at target were recorded, with LLT efficacy estimated based on percentage distance from LDL-cholesterol targets. Results: Of the 1909 patients, 41.3% met the LDL-cholesterol target. Predictors of achieving targets included male gender, cardiac rehabilitation, recent acute coronary syndrome, diabetes, and triple therapy (statin + ezetimibe + PCSK9 inhibitors). Conversely, a target of ≤40 mg/dL, lack of therapy, and monotherapy were negative predictors. Among 1074 patients not at target, LLT modifications were proposed for 48.6%. Predictors of LLT modification included recent ASCVD events, cardiac rehabilitation, and greater percentage distance from the LDL target, while advanced age and an LDL target of ≤40 mg/dL were negative predictors. However, only 42.3% of modified therapies were predicted to be effective in reaching LDL targets. Conclusions: Despite 2019 ESC/EAS guidelines, a significant proportion of high-risk patients did not achieve LDL targets, and proposed LLT modifications were often insufficient. More intensive LLT regimens are needed to improve outcomes in this population.
DNA methylation in cardiovascular disease and heart failure: novel prediction models? Antonella Desiderio, Monica Pastorino, Michele Campitelli, Michele Longo, Claudia Miele, Raffaele Napoli, Francesco Beguinot, Gregory Alexander Raciti Clinical Epigenetics, 2024 BACKGROUND: Cardiovascular diseases (CVD) affect over half a billion people worldwide and are the leading cause of global deaths. In particular, due to population aging and worldwide spreading of risk factors, the prevalence of heart failure (HF) is also increasing. HF accounts for approximately 36% of all CVD-related deaths and stands as the foremost cause of hospitalization. Patients affected by CVD or HF experience a substantial decrease in health-related quality of life compared to healthy subjects or affected by other diffused chronic diseases. MAIN BODY: For both CVD and HF, prediction models have been developed, which utilize patient data, routine laboratory and further diagnostic tests. While some of these scores are currently used in clinical practice, there still is a need for innovative approaches to optimize CVD and HF prediction and to reduce the impact of these conditions on the global population. Epigenetic biomarkers, particularly DNA methylation (DNAm) changes, offer valuable insight for predicting risk, disease diagnosis and prognosis, and for monitoring treatment. The present work reviews current information relating DNAm, CVD and HF and discusses the use of DNAm in improving clinical risk prediction of CVD and HF as well as that of DNAm age as a proxy for cardiac aging. CONCLUSION: DNAm biomarkers offer a valuable contribution to improving the accuracy of CV risk models. Many CpG sites have been adopted to develop specific prediction scores for CVD and HF with similar or enhanced performance on the top of existing risk measures. In the near future, integrating data from DNA methylome and other sources and advancements in new machine learning algorithms will help develop more precise and personalized risk prediction methods for CVD and HF.
Exercise-training and smiling: two faces of the same coin! Francesco Giallauria, Raffaele Napoli European Journal of Preventive Cardiology, 2024 Maintaining or improving physical activity levels in elderly individuals is of the greatest importance to support their overall well-being and improve any healthcare intervention.Consistently, exercise-based cardiac rehabilitation (CR) is effective in reducing morbidity and mortality.However, its practical implementation must deal with many obstacles and challenges, for
Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: Real-world evidence from the AT-TARGET-IT registry Paola Gargiulo, Christian Basile, Gennaro Galasso, Michele Bellino, Debora D’Elia, Giuseppe Patti, Manuel Bosco, Matteo Prinetti, Giuseppe Andò, Francesca Campanella, Giovanni Taverna, Paolo Calabrò, Arturo Cesaro, Fabio Fimiani, Angelo Catalano, Ferdinando Varbella, Antonella Corleto, Francesco Barillà, Saverio Muscoli, Giuseppe Musumeci, Fabrizio Delnevo, Francesco Giallauria, Raffaele Napoli, Italo Porto, Alberto Polimeni, Rossella Quarta, Alessandro Maloberti, Piera Angelica Merlini, Leonardo De Luca, Gavino Casu, Natale Daniele Brunetti, Mario Crisci, Leonardo Paloscia, Claudio Bilato, Ciro Indolfi, Federica Marzano, Sara Fontanarosa, Davide Buonocore, Antonio Luca Maria Parlati, Ermanno Nardi, Maria Prastaro, Andrea Soricelli, Marco Salvatore, Stefania Paolillo, Pasquale Perrone-Filardi, Gianluigi Cuomo, Crescenzo Testa, Gianluca Passaretti, Giuseppe Vallefuoco, Annalisa Romano, Raffaele Dell’Anno, Aurora Merolla, Francesca Paola Iannone European Journal of Preventive Cardiology, 2024 Aims No data are available on early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in patients with acute coronary syndrome (ACS) in the real world. This study investigates the effects of PCSK9i started at time of ACS hospitalization on lipid control and major cardiovascular (CV) events in the real world. Methods and results The lipid control outcome was the percentage of patients reaching the LDL-C target of <55 mg/dL at first lipid control. The clinical outcome was the incidence of composite major CV events (all-cause death, non-fatal MI, non-fatal stroke, and ischaemia-driven revascularization) during a follow-up in relation to quartiles of LDL-C at first lipid control. We included 771 patients with ACS from the AT-TARGET-IT registry, receiving PCSK9i prescription during hospitalization or at discharge. Median LDL-C was 137 mg/dL and decreased to 43 mg/dL at first lipid control. 527 (68.3%) patients achieved LDL-C target at the first lipid control at a median time of 37 days from hospitalization; of them, 404 (76.8%) were discharged on statin plus ezetimibe background therapy. Event curves through a median follow-up of 11 months across quartiles of LDL-C showed a stepwise lower risk of 4P-MACE, 3P-MACE, all-cause mortality, and ischaemia-driven revascularization in lower quartile of LDL-C values at first lipid control (<23 mg/dL) and in patients reaching LDL-C < 55 mg/dL. Conclusion Intensive and early lipid-lowering therapy using PCSK9i in patients with ACS (strike early–strike strong strategy) is safe and effective in clinical practice and associated with a reduction of residual CV risk.
Treatment intensification following glucagon-like peptide-1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE-G real-world study Raffaele Napoli, Antonio Nicolucci, Monica Larosa, Maria Chiara Rossi, Riccardo Candido, and Diabetes Obesity and Metabolism, 2024 AimTo compare the effectiveness of different basal insulins (BI) prescribed as an add‐on to or switch from glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy.Materials and MethodsRetrospective, real‐world data from electronic medical records of 32 Italian diabetes clinics were used, after propensity score adjustment, to compare effectiveness after 6 months of treatment with second‐ versus first‐generation BI (2BI vs. 1BI) or glargine 300 U/ml versus degludec 100 U/ml (Gla‐300 vs. Deg‐100), when added to (ADD‐ON) or in substitution of (SWITCH) GLP‐1 RA. Only comparisons, including a minimum of 100 patients per group, were performed to ensure adequate robustness of the analyses.ResultsIn the ADD‐ON cohort (N = 700), greater benefits of 2BI versus 1BI were found in glycated haemoglobin {HbA1c; estimated mean difference: −0.32% [95% confidence interval (CI) −0.62; −0.02]; p = .04} and fasting blood glucose [FBG; −20.73 mg/dl (95% CI −35.62; −5.84); p = .007]. In the SWITCH cohort (N = 2097), greater benefits of 2BI versus 1BI were found in HbA1c [−0.22% (95% CI −0.42; −0.02); p = .03], FBG [−10.15 mg/dl (95% CI −19.04; −1.26); p = .03], and body weight [−0.67 kg (95% CI −1.30; −0.04); p = .04]. In the SWITCH cohort starting 2BI (N = 688), marked differences in favour of Gla‐300 versus Deg‐100 were documented in HbA1c [−0.89% (95% CI −1.26; −0.52); p < .001] and FBG [−17.89 mg/dl (95% CI −32.45; −3.33); p = .02]. Using propensity score matching as a sensitivity analysis, the benefit on HbA1c was confirmed [−0.55% (95% CI –1.02; −0.08); p = .02]. BI titration was suboptimal in all examined cohorts.Conclusions2BI are a valuable option to intensify GLP‐1 RA therapy. Switching to Gla‐300 versus Deg‐100 was associated with greater HbA1c improvement.
Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study Riccardo Candido, Antonio Nicolucci, Monica Larosa, Maria Chiara Rossi, Raffaele Napoli, Enrico Gabellieri, Elena Tortato, Rosa Anna Rabini, Dalia Crazzolara, Luigi Lucibelli, Concetta Aragiusto, Gianluigi Panzolato, Maurizio Di Mauro, Andrea Del Buono, Giuseppe Placentino, Graziano Di Cianni, Gabriele Brandoni, Stefano Fazion, Giovanna Gregori, Antonino Di Benedetto, Carlo De Riva, Annamaria Terracciano, Luciano Zenari, Giuseppe Placentino, Franco Cavalot, Francesca Porcellati, Roberto Anichini, Giuseppe Citro, Paola D'Angelo, Marcello Arca, Lelio Morviducci, Rosa Anna Rabini, Valeria Montani, Luigi Lucibelli, Giuseppe Placentino, Paolo Fiorentini Nutrition Metabolism and Cardiovascular Diseases, 2024
Dopamine Pharmacodynamics: New Insights Fulvio Lauretani, Francesco Giallauria, Crescenzo Testa, Claudia Zinni, Beatrice Lorenzi, Irene Zucchini, Marco Salvi, Raffaele Napoli, Marcello Giuseppe Maggio International Journal of Molecular Sciences, 2024 Dopamine is a key neurotransmitter involved in physiological processes such as motor control, motivation, reward, cognitive function, and maternal and reproductive behaviors. Therefore, dysfunctions of the dopaminergic system are related to a plethora of human diseases. Dopamine, via different circuitries implicated in compulsive behavior, reward, and habit formation, also represents a key player in substance use disorder and the formation and perpetuation of mechanisms leading to addiction. Here, we propose dopamine as a model not only of neurotransmission but also of neuromodulation capable of modifying neuronal architecture. Abuse of substances like methamphetamine, cocaine, and alcohol and their consumption over time can induce changes in neuronal activities. These modifications lead to synaptic plasticity and finally to morphological and functional changes, starting from maladaptive neuro-modulation and ending in neurodegeneration.
Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study Riccardo Candido, Antonio Nicolucci, Monica Larosa, Maria Chiara Rossi, Raffaele Napoli, Enrico Gabellieri, Elena Tortato, Rosa Anna Rabini, Dalia Crazzolara, Luigi Lucibelli, Concetta Aragiusto, Gianluigi Panzolato, Maurizio Di Mauro, Andrea Del Buono, Giuseppe Placentino, Graziano Di Cianni, Gabriele Brandoni, Stefano Fazion, Giovanna Gregori, Antonino Di Benedetto, Carlo De Riva, Annamaria Terracciano, Raffaele Napoli, Luciano Zenari, Giuseppe Placentino, Franco Cavalot, Francesca Porcellati, Roberto Anichini, Giuseppe Citro, Paola D'Angelo, Marcello Arca, Lelio Morviducci, Rosa Anna Rabini, Valeria Montani, Luigi Lucibelli, Giuseppe Placentino, Paolo Fiorentini Nutrition Metabolism and Cardiovascular Diseases, 2023 BACKGROUND AND AIMS: To assess intensification approaches with basal insulin (BI) following glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment in type 2 diabetes (T2D). METHODS AND RESULTS: Real-world data were collected in electronic medical records by 32 Italian diabetes clinics between 2011 and 2021. Primary endpoint was the proportion of insulin-naïve T2D patients treated with GLP-1 RA who initiated (add-on or switch) BI. Secondary endpoints were: treatment approaches, mean time to BI start, effectiveness and safety. Among 7,962 eligible patients, BI was prescribed to 3,164 (39.7%; 95%CI 38.7; 40.8): 67.6% switched to BI (22.1% also starting 1-3 injections of short-acting insulin), 22.7% added BI while maintaining GLP-1 RA, and 9.7% switched to a fixed-ratio combination of GLP-1 RA and BI (FRC). Median time since the first GLP-1 RA to BI/FRC prescription was 27.4 (IQ range 11.8-53.5) months. In this study 60.3% of patients did not start BI/FRC, among whom 15.2% intensified GLP-1 RA therapy with other oral agents. Effectiveness and safety were documented in all intensification approaches with BI/FRC, but HbA1c level at intensification time of ≥9.0% and suboptimal BI titration suggested clinical inertia. Use of second generation BI and add-on to GLP-1 RA schemes increased over time and effectiveness improved. CONCLUSION: Clinical inertia should be overcome using innovative insulin options. Timely combination therapy of BI and GLP-1 RA is a valuable choice.
Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment Andrea de Bartolomeis, Giuseppe De Simone, Michele De Prisco, Annarita Barone, Raffaele Napoli, Francesco Beguinot, Martina Billeci, Michele Fornaro Molecular Psychiatry, 2023 Impairment of insulin action and metabolic dysregulation have traditionally been associated with schizophrenia, although the molecular basis of such association remains still elusive. The present meta-analysis aims to assess the impact of insulin action manipulations (i.e., hyperinsulinemia, hypoinsulinemia, systemic or brain insulin resistance) on glutamatergic, dopaminergic, γ-aminobutyric acid (GABA)ergic, and serotonergic pathways in the central nervous system. More than one hundred outcomes, including transcript or protein levels, kinetic parameters, and other components of the neurotransmitter pathways, were collected from cultured cells, animals, or humans, and meta-analyzed by applying a random-effects model and adopting Hedges’g to compare means. Two hundred fifteen studies met the inclusion criteria, of which 180 entered the quantitative synthesis. Significant impairments in key regulators of synaptic plasticity processes were detected as the result of insulin handlings. Specifically, protein levels of N-methyl-D-aspartate receptor (NMDAR) subunits including type 2A (NR2A) (Hedges’ g = −0.95, 95%C.I. = −1.50, −0.39; p = 0.001; I2 = 47.46%) and 2B (NR2B) (Hedges’g = −0.69, 95%C.I. = −1.35, −0.02; p = 0.043; I2 = 62.09%), and Postsynaptic density protein 95 (PSD-95) (Hedges’g = −0.91, 95%C.I. = −1.51, −0.32; p = 0.003; I2 = 77.81%) were found reduced in insulin-resistant animal models. Moreover, insulin-resistant animals showed significantly impaired dopamine transporter activity, whereas the dopamine D2 receptor mRNA expression (Hedges’g = 3.259; 95%C.I. = 0.497, 6.020; p = 0.021; I2 = 90.61%) increased under insulin deficiency conditions. Insulin action modulated glutamate and GABA release, as well as several enzymes involved in GABA and serotonin synthesis. These results suggest that brain neurotransmitter systems are susceptible to insulin signaling abnormalities, resembling the discrete psychotic disorders’ neurobiology and possibly contributing to the development of neurobiological hallmarks of treatment-resistant schizophrenia.
Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. Registry Andrea Salzano, Roberta D’Assante, Massimo Iacoviello, Vincenzo Triggiani, Giuseppe Rengo, Francesco Cacciatore, Ciro Maiello, Giuseppe Limongelli, Daniele Masarone, Angela Sciacqua, Pasquale Perrone Filardi, Antonio Mancini, Maurizio Volterrani, Olga Vriz, Roberto Castello, Andrea Passantino, Michela Campo, Pietro A. Modesti, Alfredo De Giorgi, Michele Arcopinto, Paola Gargiulo, Maria Perticone, Annamaria Colao, Salvatore Milano, Agnese Garavaglia, Raffaele Napoli, Toru Suzuki, Eduardo Bossone, Alberto M. Marra, Antonio Cittadini, A. Cittadini, A. M. Marra, M. Arcopinto, R. D’Assante, L. Saccà, M. G. Monti, R. Napoli, M. Matarazzo, F. M. Stagnaro, L. Piccioli, A. Lombardi, V. Panicara, M. Flora, L. Golia, V. Faga, A. Ruocco, D. Della Polla, R. Franco, A. Schiavo, A. Gigante, E. Spina, M. Sicuranza, F. Monaco, M. Apicella, C. Miele, A. G. Campanino, L. Mazza, R. Abete, A. Farro, F. Luciano, R. Polizzi, G. Ferrillo, M. De Luca, G. Crisci, F. Giardino, M. Barbato, A. Salzano, B. Ranieri, E. Bossone, F. Ferrara, V. Russo, M. Malinconico, R. Citro, E. Guastalamacchia, M. Iacoviello, M. Leone, V. Triggiani, V. A. Giagulli, F. Cacciatore, C. Maiello, C. Amarelli, I. Mattucci, G. Limongelli, D. Masarone, P. Calabrò, R. Calabrò, A. D’Andrea, V. Maddaloni, G. Pacileo, R. Scarafile, F. Perticone, A. Belfiore, A. Sciacqua, A. Cimellaro, P. Perrone Filardi, L. Casaretti, S. Paolillo, P. Gargiulo, A. Mancini, A. M. R. Favuzzi, C. Di Segni, C. Bruno, E. Vergani, M. Volterrani, R. Massaro, O. Vriz, F. Grimaldi, R. Castello, A. Frigo, M. R. Campo, M. R. Sorrentino, P. A. Modesti, D. Malandrino, R. Manfredini, A. De Giorgi, F. Fabbian, A. Puzzo, L. Ragusa, L. Caliendo, L. Carbone, A. Frigiola, T. Generali, F. Giacomazzi, C. De Vincentiis, A. Ballotta, P. Garofalo, G. Malizia, S. Milano, G. Misiano, T. Suzuki, M. Z. Israr, D. Bernieh, S. Cassambai, Y. Yazaki, L. M. Heaney, K. A. Eagle, H. O. Ventura, A. Colao, D. Bruzzese, and Cardiovascular Diabetology, 2022
Exposure to artificial light at night: A common link for obesity and cancer? Giovanna Muscogiuri, Eleonora Poggiogalle, Luigi Barrea, Maria G. Tarsitano, Francesco Garifalos, Alessia Liccardi, Gabriella Pugliese, Silvia Savastano, Annamaria Colao, Annamaria Colao, Carlo Alviggi, Sara Aprano, Rocco Barazzoni, Luigi Barrea, Francesco Beguinot, Annamaria Belfiore, Giuseppe Bellastella, Silvia Bettini, Giuseppe Bifulco, Maurizio Bifulco, Caterina Brasacchio, Filomena Bottiglieri, Luca Busetto, Brunella Capaldo, Massimiliano Caprio, Felipe Casanueva, Luigi Di Luigi, Andrea Di Nisio, Laura Di Renzo, Carolina Di Somma, Lorenzo M. Donini, Katherine Esposito, Massimo Federici, Francesco Garifalos, Dario Giugliano, Lucio Gnessi, Gianluca G. Cappellari, Brunella Guida, Maria A. Guzzardi, Daniela Laudisio, Andrea Lenzi, Alessia Liccardi, Carla Lubrano, Paolo E. Macchia, Silvia Magno, Paolo Marzullo, Davide Menafra, Silvia Migliaccio, Fabrizio Muratori, Giovanna Muscogiuri, Raffaele Napoli, Caterina Pelosini, Francesca Pivari, Rosario Pivonello, Eleonora Poggiogalle, Gabriella Pugliese, Gabriele Riccardi, Alberto Ritieni, Fiammetta Romano, Domenico Salvatore, Alessandro Sanduzzi, Ferruccio Santini, Silvia Savastano, Paolo Sbraccia, Giovanni S.L. Soldati, Giovanni Spera, Maria G. Tarsitano, Dario Tuccinardi, Olga Vaccaro, Mary Venneri, Samir Sukkar, Roberto Vettor European Journal of Cancer, 2022
Insulin-like growth factor-1 (IGF-1) as predictor of cardiovascular mortality in heart failure patients: data from the T.O.S.CA. registry Alfredo De Giorgi, Alberto Maria Marra, Massimo Iacoviello, Vincenzo Triggiani, Giuseppe Rengo, Francesco Cacciatore, Ciro Maiello, Giuseppe Limongelli, Daniele Masarone, Francesco Perticone, Pasquale Perrone Filardi, Stefania Paolillo, Antonio Mancini, Maurizio Volterrani, Olga Vriz, Roberto Castello, Andrea Passantino, Michela Campo, Pietro Amedeo Modesti, Andrea Salzano, Roberta D’Assante, Michele Arcopinto, Valeria Raparelli, Fabio Fabbian, Angela Sciacqua, Annamaria Colao, Toru Suzuki, Eduardo Bossone, Antonio Cittadini, A. Cittadini, M. A. ArcopintoSalzano, L. Saccà, M. G. Monti, R. Napoli, M. Matarazzo, F. M. Stagnaro, A. Schiavo, P. Valente, E. Bossone, F. Ferrara, V. Russo, M. Malinconico, R. Citro, E. Guastalamacchia, M. Iacoviello, M. Leone, V. Triggiani, F. Cacciatore, C. Maiello, C. Amarelli, I. Mattucci, G. Limongelli, D. Masarone, P. Calabrò, R. Calabrò, A. D’Andrea, V. Maddaloni, G. Pacileo, R. Scarafile, F. Perticone, A. Belfiore, A. Sci-acqua, A. Cimellaro, P. Perrone Filardi, L. Casaretti, S. Paolillo, P. Gargiulo, A. Mancini, A. M. R. Favuzzi, C. Di Segni, C. Bruno, E. Vergani, O. Vriz, R. Castello, A. Frigo, M. Campo, M. R. Sorrentino, P. A. Modesti, D. Malandrino, R. Manfredini, A. De Giorgi, F. Fabbian, A. Puzzo, L. Ragusa, L. Caliendo, L. Carbone, A. Frigiola, T. Generali, F. Giacomazzi, C. De Vincentiis, A. Ballotta, P. Garofalo, G. Malizia, T. Suzuki, L. M. Heaney, D. Bruzzese, and Internal and Emergency Medicine, 2022
Spot-light on microbiota in obesity and cancer Paolo Marzullo, Silvia Bettini, Davide Menafra, Sara Aprano, Giovanna Muscogiuri, Luigi Barrea, Silvia Savastano, Annamaria Colao, Annamaria Colao, Silvia Savastano, Silvia Magno, Andrea Di Nisio, Fiammetta Romano, Giovanna Muscogiuri, Eleonora Poggiogalle, Mary Venneri, Alessia Liccardi, Maria Grazia Tarsitano, Luigi Barrea, Laura Di Renzo, Dario Tuccinardi, Massimiliano Caprio, Maria Angela Guzzardi, Caterina Pelosini, Gabriella Pugliese, Filomena Bottiglieri, Sara Aprano, Davide Menafra, Gianluca Gortan Capellari, Daniela Laudisio, Francesca Pivari, Caterina Brasacchio, Andrea Lenzi, Fabrizio Muratori, Ferruccio Santini, Luca Busetto, Paolo Sbraccia, Laura Soldati, Domenico Salvatore, Carolina Di Somma, Dario Giugliano, Lucio Gnessi, Brunella Capaldo, Gabriele Riccardi, Rocco Barazzoni, Brunella Guida, Maurizio Bifulco, Katherine Esposito, Roberto Vettor, Paolo Emidio Macchia, Felipe Casanueva, Carla Lubrano, Francesco Beguinot, Giovanni Spera, Annamaria Belfiore, Luigi Di Luigi, Alberto Ritieni, Raffaele Napoli, Olga Vaccaro, Samir Sukkar, Carlo Alviggi, Rosario Pivonello, Giuseppe Bellastella, Giovanni Scambia, Giuseppe Bifulco, and International Journal of Obesity, 2021
Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry Antonio Cittadini, Andrea Salzano, Massimo Iacoviello, Vincenzo Triggiani, Giuseppe Rengo, Francesco Cacciatore, Ciro Maiello, Giuseppe Limongelli, Daniele Masarone, Francesco Perticone, Antonio Cimellaro, Pasquale Perrone Filardi, Stefania Paolillo, Antonio Mancini, Maurizio Volterrani, Olga Vriz, Roberto Castello, Andrea Passantino, Michela Campo, Pietro A Modesti, Alfredo De Giorgi, Ines P Monte, Alfonso Puzzo, Andrea Ballotta, Roberta D’Assante, Michele Arcopinto, Paola Gargiulo, Angela Sciacqua, Dario Bruzzese, Annamaria Colao, Raffaele Napoli, Toru Suzuki, Kim A Eagle, Hector O Ventura, Alberto M Marra, Eduardo Bossone, and European Journal of Preventive Cardiology, 2021
Immunoglobulins G modulate endothelial function and affect insulin sensitivity in humans Raffaele Napoli, Antonio Ruvolo, Paola Triggianese, Nella Prevete, Gabriele G. Schiattarella, Cecilia Nigro, Claudia Miele, Fabio Magliulo, Simona Grassi, Antonio Pecoraro, Antonio Cittadini, Giovanni Esposito, Amato de Paulis, Giuseppe Spadaro Nutrition Metabolism and Cardiovascular Diseases, 2020
Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction Andrea Salzano, Alberto Maria Marra, Francesco Ferrara, Michele Arcopinto, Emanuele Bobbio, Pietro Valente, Roberto Polizzi, Carlo De Vincentiis, Margherita Matarazzo, Lavinia Saldamarco, Francesco Saccà, Raffaele Napoli, Maria Gaia Monti, Roberta D’Assante, Andrea M. Isidori, Jorgen Isgaard, Nicola Ferrara, Pasquale Perrone Filardi, Francesco Perticone, Carlo Vigorito, Eduardo Bossone, Antonio Cittadini International Journal of Cardiology, 2016
Multiple hormone deficiencies in chronic heart failure Michele Arcopinto, Andrea Salzano, Eduardo Bossone, Francesco Ferrara, Emanuele Bobbio, Domenico Sirico, Olga Vriz, Carlo De Vincentiis, Margherita Matarazzo, Lavinia Saldamarco, Francesco Saccà, Raffaele Napoli, Massimo Iacoviello, Vincenzo Triggiani, Andrea M. Isidori, Carlo Vigorito, Jorgen Isgaard, Antonio Cittadini International Journal of Cardiology, 2015
Cardiovascular abnormalities in Klinefelter syndrome Daniela Pasquali, Michele Arcopinto, Andrea Renzullo, Mario Rotondi, Giacomo Accardo, Andrea Salzano, Daniela Esposito, Lavinia Saldamarco, Andrea M. Isidori, Alberto M. Marra, Antonio Ruvolo, Raffaele Napoli, Eduardo Bossone, Andrea Lenzi, Ragavendra R. Baliga, Luigi Saccà, Antonio Cittadini International Journal of Cardiology, 2013
The GH/IGF-1 axis in chronic heart failure Michele Arcopinto, Emanuele Bobbio, Eduardo Bossone, Pasquale Perrone-Filardi, Raffaele Napoli, Luigi Sacca, Antonio Cittadini Endocrine Metabolic and Immune Disorders Drug Targets, 2013
Human immunodeficiency virus per se exerts atherogenic effects Ugo Oliviero, Giovanni Bonadies, Valentina Apuzzi, Maria Foggia, Giorgio Bosso, Salvatore Nappa, Antonio Valvano, Enrico Leonardi, Guglielmo Borgia, Giuseppe Castello, Raffaele Napoli, Luigi Saccà Atherosclerosis, 2009
Recombinant human thyrotropin enhances endothelial-mediated vasodilation of conduit arteries Raffaele Napoli, Valentina Apuzzi, Giorgio Bosso, Carolina D'Anna, Antonietta De Sena, Concetta Pirozzi, Aldo Marano, Gelsy Arianna Lupoli, Giuseppe Cudemo, Ugo Oliviero, Margherita Matarazzo, Giovanni Lupoli, Luigi Saccá Journal of Clinical Endocrinology and Metabolism, 2009
Enhancement of vascular endothelial function by recombinant human thyrotropin Raffaele Napoli, Bernadette Biondi, Vincenzo Guardasole, Carolina D'Anna, Antonietta De Sena, Concetta Pirozzi, Daniela Terracciano, Claudia Mazzarella, Margherita Matarazzo, Luigi Saccà Journal of Clinical Endocrinology and Metabolism, 2008
Detection of growth hormone abuse in sport J.K. Powrie, E.E. Bassett, T. Rosen, J.O. Jørgensen, R. Napoli, L. Sacca, J.S. Christiansen, B.A. Bengtsson, P.H. Sönksen Growth Hormone and IGF Research, 2007
Acute effects of triiodothyronine on endothelial function in human subjects Raffaele Napoli, Vincenzo Guardasole, Valentina Angelini, Emanuela Zarra, Daniela Terracciano, Carolina D’Anna, Margherita Matarazzo, Ugo Oliviero, Vincenzo Macchia, Luigi Saccà Journal of Clinical Endocrinology and Metabolism, 2007
Long-term normalization of GLUT 4 protein content in skeletal muscle of streptozotocin-diabetic Lewis rats after islet transplantation Transplantation Proceedings, 1995
Impaired stimulation of gluconeogenesis during prolonged hypoglycemia in intensively treated insulin-dependent diabetic subjects Journal of Clinical Endocrinology and Metabolism, 1992
Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension Journal of Clinical Investigation, 1992
Glucose and gluconeogenic substrate exchange by the forearm skeletal muscle in hyperglycemic and insulin-treated type II diabetic patients Journal of Clinical Endocrinology and Metabolism, 1990
Role of the splanchnic tissues in the pathogenesis of altered carbohydrate metabolism in patients with chronic renal failure Journal of Clinical Endocrinology and Metabolism, 1990
Splanchnic exchange of glucose and gluconeogenic substrates in physiology and in type II diabetes Diabetes Obesity and Hyperlipidemias IV Proceedings of the 5th European Symposium on Metabolism Ics872, 1990
Long-term efficacy of ibopamine in chronic congestive heart failure: Assessment by electrical transthoracic impedance Current Therapeutic Research Clinical and Experimental, 1990
Cataract formation in patients with lactose and galactose disorders. Developments in Ophthalmology, 1989
Metabolic changes in the skeletal muscle of non-insulin-dependent diabetics Minerva Endocrinologica, 1988
